Atomwise, which uses AI to improve drug discovery, raises $45M Series A

 Atomwise, which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A. The round was led by Monsanto Growth Ventures, Data Collective (DCVC) and B Capital Group. Baidu Ventures, Tencent and Dolby Family Ventures, which are all new investors in Atomwise, also participated, as well as returning investors Y Combinator, Khosla Ventures and DFJ. Read More
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.